Citation bot: Add: display-authors, pmid, volume, journal, date, title, authors 1-30. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webform
{{Infobox drug
| drug_name = Gumarontinib
| INN =
| type = <!-- empty -->
| image = Gumarontinib.svg
| alt =
| caption =
<!-- Clinical data -->
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = Oral
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Rx in China
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
<!-- Identifiers -->
| synonyms = Glumetinib; SCC244; SC-C244
| CAS_number = 1642581-63-2
| PubChem = 117797905
| UNII = 7JTT036WGX
| DrugBank =
<!-- Chemical and physical data -->
| IUPAC_name = 6-(1-Methylpyrazol-4-yl)-1-[6-(1-methylpyrazol-4-yl)imidazo[1,2-''a'']pyridin-3-yl]sulfonylpyrazolo[4,3-''b'']pyridine
| C = 21 | H = 17 | N = 9 | O = 2 | S = 1
}}
'''Gumarontinib''' is a pharmaceutical drug for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or [[metastatic]] [[non-small cell lung cancer]] (NSCLC) with MET exon 14 skipping mutation.<ref>{{cite news | url = https://ecancer.org/en/news/22782-n...ung-cancer-with-met-exon-14-skipping-mutation | website = ecancer.org | title = NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation | date = March 10, 2023 }}</ref>
Gumarontinib is a selective [[mesenchymal–epithelial transition]] (MET) inhibitor.<ref>{{cite journal | doi = 10.1016/j.eclinm.2023.101952 | title = Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: A multicentre, single-arm, open-label, phase 1b/2 trial | date = 2023 | last1 = Yu | first1 = Yongfeng | last2 = Zhou | first2 = Jianya | last3 = Li | first3 = Xingya | last4 = Goto | first4 = Koichi | last5 = Min | first5 = Xuhong | last6 = Nishino | first6 = Kazumi | last7 = Cui | first7 = Jiuwei | last8 = Wu | first8 = Lin | last9 = Sakakibara | first9 = Jun | last10 = Shu | first10 = Yongqian | last11 = Dong | first11 = Xiaorong | last12 = Li | first12 = Lu | last13 = Yoneshima | first13 = Yasuto | last14 = Zhou | first14 = Chengzhi | last15 = Li | first15 = Xiaoling | last16 = Zhang | first16 = Yiping | last17 = Huang | first17 = Dingzhi | last18 = Zang | first18 = Aimin | last19 = Zhang | first19 = Wei | last20 = Wang | first20 = Xiuwen | last21 = Zhang | first21 = Li | last22 = Bai | first22 = Chong | last23 = Fang | first23 = Jian | last24 = Cao | first24 = Lejie | last25 = Zhao | first25 = Yanqiu | last26 = Yu | first26 = Yan | last27 = Shi | first27 = Meiqi | last28 = Zhong | first28 = Diansheng | last29 = Li | first29 = Fugen | last30 = Li | first30 = Meng | journal = eClinicalMedicine | volume = 59 | pmid = 37096188 | display-authors = 1 }}</ref>
==References==
{{reflist}}
{{antineoplastic-drug-stub}}
[[Category:Antineoplastic and immunomodulating drugs]]
[[Category
yrazolopyridines]]
[[Category:Imidazopyridines]]
[[Categoryyrazoles]]
[[Category:Sulfonamides]]
[[Category:Kinase inhibitors]]
Okumaya devam et...
{{Infobox drug
| drug_name = Gumarontinib
| INN =
| type = <!-- empty -->
| image = Gumarontinib.svg
| alt =
| caption =
<!-- Clinical data -->
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = Oral
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Rx in China
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
<!-- Identifiers -->
| synonyms = Glumetinib; SCC244; SC-C244
| CAS_number = 1642581-63-2
| PubChem = 117797905
| UNII = 7JTT036WGX
| DrugBank =
<!-- Chemical and physical data -->
| IUPAC_name = 6-(1-Methylpyrazol-4-yl)-1-[6-(1-methylpyrazol-4-yl)imidazo[1,2-''a'']pyridin-3-yl]sulfonylpyrazolo[4,3-''b'']pyridine
| C = 21 | H = 17 | N = 9 | O = 2 | S = 1
}}
'''Gumarontinib''' is a pharmaceutical drug for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or [[metastatic]] [[non-small cell lung cancer]] (NSCLC) with MET exon 14 skipping mutation.<ref>{{cite news | url = https://ecancer.org/en/news/22782-n...ung-cancer-with-met-exon-14-skipping-mutation | website = ecancer.org | title = NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation | date = March 10, 2023 }}</ref>
Gumarontinib is a selective [[mesenchymal–epithelial transition]] (MET) inhibitor.<ref>{{cite journal | doi = 10.1016/j.eclinm.2023.101952 | title = Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: A multicentre, single-arm, open-label, phase 1b/2 trial | date = 2023 | last1 = Yu | first1 = Yongfeng | last2 = Zhou | first2 = Jianya | last3 = Li | first3 = Xingya | last4 = Goto | first4 = Koichi | last5 = Min | first5 = Xuhong | last6 = Nishino | first6 = Kazumi | last7 = Cui | first7 = Jiuwei | last8 = Wu | first8 = Lin | last9 = Sakakibara | first9 = Jun | last10 = Shu | first10 = Yongqian | last11 = Dong | first11 = Xiaorong | last12 = Li | first12 = Lu | last13 = Yoneshima | first13 = Yasuto | last14 = Zhou | first14 = Chengzhi | last15 = Li | first15 = Xiaoling | last16 = Zhang | first16 = Yiping | last17 = Huang | first17 = Dingzhi | last18 = Zang | first18 = Aimin | last19 = Zhang | first19 = Wei | last20 = Wang | first20 = Xiuwen | last21 = Zhang | first21 = Li | last22 = Bai | first22 = Chong | last23 = Fang | first23 = Jian | last24 = Cao | first24 = Lejie | last25 = Zhao | first25 = Yanqiu | last26 = Yu | first26 = Yan | last27 = Shi | first27 = Meiqi | last28 = Zhong | first28 = Diansheng | last29 = Li | first29 = Fugen | last30 = Li | first30 = Meng | journal = eClinicalMedicine | volume = 59 | pmid = 37096188 | display-authors = 1 }}</ref>
==References==
{{reflist}}
{{antineoplastic-drug-stub}}
[[Category:Antineoplastic and immunomodulating drugs]]
[[Category
yrazolopyridines]][[Category:Imidazopyridines]]
[[Category
yrazoles]][[Category:Sulfonamides]]
[[Category:Kinase inhibitors]]
Okumaya devam et...